Zhengye Biotechnology Holding LtdZYBT
Price (close)
$1.31
Market cap
$62.1M
P/E
—
Revenue (FY)
$116.4M
Net income
-$69.8M
Dividend yield
—
1-year total return
-56.3%
Net margin
-60.0%
Revenue growth
-37.6%
Debt / equity
0.30x
What Zhengye Biotechnology Holding Ltd does.
mission is to become a world-leading manufacturer of veterinary vaccines and to provide reliable veterinary vaccines to the world.
through the operating entity, focus on the research, development, manufacturing and sales of veterinary vaccines, with an emphasis on
vaccines for livestock. For over 20 years, the operating entity has been committed to enhancing the health of animals. The operating
Revenue and profit, by fiscal year.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | — | $260.3M | $211.7M | $186.4M | $116.4M |
| Net income | — | $46.7M | $31.5M | $11.3M | -$69.8M |
| Free cash flow | — | -$10.0M | $40.8M | $27.5M | $12.3M |
More on ZYBT.
- Zhengye Biotechnology Holding Ltd summary
- Zhengye Biotechnology Holding Ltd financial statements
- Zhengye Biotechnology Holding Ltd key metrics
- Zhengye Biotechnology Holding Ltd health scores and style box
- Zhengye Biotechnology Holding Ltd earnings
- Zhengye Biotechnology Holding Ltd dividends
- Zhengye Biotechnology Holding Ltd valuation
- Zhengye Biotechnology Holding Ltd ownership and insiders
- Zhengye Biotechnology Holding Ltd peers
Figures from Zhengye Biotechnology Holding Ltd's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.